Catecholamine release-inhibitory peptide catestatin (chromogranin A352-372): Naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension

Circulation

Volumn 115, Issue 17, 2007, Pages 2271-2281

  Rao, Fangwen ^a   Wen, Gen ^a   Gayen, Jiaur R ^a   Das, Madhusudan ^a   Vaingankar, Sucheta M ^a   Rana, Brinda K ^b,e   Mahata, Manjula ^a   Kennedy, Brian P ^a   Salem, Rany M ^a   Stridsberg, Mats ^g   Abel, Kenneth ^a   Smith, Douglas W ^e   Eskin, Eleazar ^c   Schork, Nicholas J ^b,e   Hamilton, Bruce A ^a   Ziegler, Michael G ^a   Mahata, Sushil K ^a,f,h   O'Connor, Daniel T ^a,d,e,f,h  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d San Diego   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^g UPPSALA UNIVERSITY   (Sweden)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetylcholine; Blood pressure; Catecholamines; Genetics; Heart rate; Hypertension; Nervous system, sympathetic

Indexed keywords

ADRENALIN; CATECHOLAMINE; CHROMOGRANIN A; CHROMOGRANIN A[352 372]; NORADRENALIN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADRENALIN RELEASE; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOWN REGULATION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY; MAJOR CLINICAL STUDY; MALE; NERVE CELL CULTURE; NORADRENALIN RELEASE; PARASYMPATHETIC INNERVATION; PHENOTYPE; POPULATION BASED CASE CONTROL STUDY; PRESSORECEPTOR; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SOLITARY TRACT NUCLEUS; SYMPATHETIC INNERVATION; UPREGULATION;

AMINO ACID SEQUENCE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CATECHOLAMINES; CHROMOGRANIN A; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HAPLOTYPES; HEART RATE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERTENSION; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHENOTYPE; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NICOTINIC; RISK FACTORS; SEX DISTRIBUTION; VARIATION (GENETICS);

EID: 34247617824     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.628859     Document Type: Article

References (44)

1. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134-1149.
2. Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell. 2001;106:499-509.
3. Huh YH, Jeon SH, Yoo SH. Chromogranin B-induced secretory granule biogenesis: comparison with the similar role of chromogranin A. J Biol Chem. 2003;278:40581-40589.
4. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. Novel autocrine feedback control of catecholamine release: a discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest. 1997;100:1623-1633.
5. Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O'Connor DT. Catecholamine secretory vesicle stimulus-transcription coupling in vivo: demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J Biol Chem. 2003;278:32058-32067.
6. O'Connor DT, Takiyyuddin MA, Printz MP, Dinh TQ, Barbosa JA, Rozansky DJ, Mahata SK, Wu H, Kennedy BP, Ziegler MG, Wright FA, Schlager G, Parmer RJ. Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press. 1999:285-295.
7. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA, O'Connor DT. Chromogranin A in human hypertension: influence of heredity. Hypertension. 1995;26:213-220.
8. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens. 2002;20:1335-1345.
9. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest. 2005;115:1942-1952.
10. Wen G, Mahata SK, Cadman P, Mahata M, Ghosh S, Mahapatra NR, Rao F, Stridsberg M, Smith DW, Mahboubi P, Schork NJ, O'Connor DT, Hamilton BA. Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet. 2004;74:197-207.
11. Kennedy BP, Rao F, Botiglieri T, Sharma S, Lillie EO, Ziegler MG, O'Connor DT. Contributions of the sympathetic nervous system, glutathione, body mass and gender to blood pressure increase with normal aging: influence of heredity. J Hum Hypertens. 2005;19:951-969.
12. Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E. Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. Am J Med. 2002;113:472-479.
13. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension. 2003;41:207-210.
14. Appel ML, Berger RD, Saul JP, Smith JM, Cohen RJ. Beat to beat variability in cardiovascular variables: noise or music? J Am Coll Cardiol. 1989;14:1139-1148.
15. Montano N, Ruscone TG, Porta A, Lombardi F, Pagani M, Malliani A. Power spectrum analysis of heart rate variability to assess the changes in sympathovagal balance during graded orthostatic tilt. Circ Res. 1994;90:1826-1831.
16. Toichi M, Sugiura T, Murai T, Sengoku A. A new method of assessing cardiac autonomic function and its comparison with spectral analysis and coefficient of variation of RR interval. J Autonom Nerv Syst. 1997;62:79-84.
17. Parmer RJ, Cervenka JH, Stone RA, O'Connor DT. Autonomic function in hypertension: are there racial differences? Circulation. 1990;81:1305-1311.
18. Brinton TJ, Kailasam MT, Wu RA, Cervenka JH, Chio SS, Parmer RJ, De Maria AN, O'Connor DT. Arterial compliance by cuff sphygmomanometer: application to hypertension, and early changes in subjects at genetic risk. Hypertension. 1996;28:599-603.
19. Preece NE, Nguyen M, Mahata M, Mahata SK, Mahapatra NR, Tsigelny I, O'Connor DT. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A. Regul Pept. 2004;118:75-87.
20. Mahata SK, Mahata M, Wakade AR, O'Connor DT. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol. 2000;14:1525-1535.
21. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
22. Halperin E, Eskin E. Haplotype reconstruction from genotype data using imperfect phylogeny. Bioinformatics. 2004;20:1842-2849.
23. Rosenberg NA, Nordborg M. Genealogical trees, coalescent theory and the analysis of genetic polymorphisms. Nat Rev Genet. 2002;3:380-390.
24. Bahlo M, Griffiths RC. Inference from gene trees in a subdivided population. Theor Popul Biol. 2000;57:79-95.
25. Templeton AR. Haplotype trees and modern human origins. Am J Phys Anthropol. 2005;41(suppl):33-59.
26. Stridsberg M, Eriksson B, Oberg K, Janson ET. A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept. 2004;117:219-227.
27. Taylor CV, Taupenot L, Mahata SK, Mahata M, Wu H, Yasothornsrikul S, Toneff T, Caporale C, Jiang Q, Parmer RJ, Hook VY, O'Connor DT. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A: determination of proteolytic cleavage sites in hormone storage granules. J Biol Chem. 2000;275:22905-22915.
28. Lee JC, Taylor CV, Gaucher SP, Toneff T, Taupenot L, Yasothornsrikul S, Mahata SK, Sei C, Parmer RJ, Neveu JM, Lane WS, Gibson BW, O'Connor DT, Hook VY. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin A into active catestatin secreted from neuroendocrine chromaffin cells. Biochemistry. 2003;42:6938-6946.
29. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther. 2003;305:800-811.
30. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583-1587.
31. King D, Etzel JP, Chopra S, Smith J, Cadman PE, Rao F, Funk SD, Rana BK, Schork NJ, Insel PA, O'Connor DT. Human response to alpha2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: biphasic influence of dose, age, gender, and receptor genotype. Clin Pharmacol Ther. 2005;77:388-403.
32. Parmer RJ, Cervenka JH, Stone RA. Baroreflex sensitivity and heredity in essential hypertension. Circ Res. 1992;85:497-503.
33. Tank J, Jordan J, Diedrich A, Stoffels M, Franke G, Faulhaber HD, Luft FC, Busjahn A. Genetic influences on baroreflex function in normal twins. Hypertension. 2001;37:907-910.
34. O'Connor DT, Insel PA, Ziegler MG, Hook VY, Smith DW, Hamilton BA, Taylor PW, Parmer RJ. Heredity and the autonomic nervous system in human hypertension. Curr Hypertens Rep. 2000;2:16-22.
35. Nowak SJ. Chronic hypertension produced by carotid sinus and aortic nerve section. Ann Surg. 1940;111:102-111.
36. Green MF, DeGroat AF, McDonald CH. Observations on denervation of the carotid sinuses and section of the depressor nerves as a method of producing arterial hypertension. Am J Physiol. 1935;110:513-520.
37. Carey RM, Dacey RG, Jane JA, Winn HR, Ayers CR, Tyson GW. Production of sustained hypertension by lesions in the nucleus tractus solitarius of the American foxhound. Hypertension. 1979;1:246-254.
38. Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;43:306-311.
39. Tank J, Diedrich A, Szczech E, Luft FC, Jordan J. Alpha-2 adrenergic transmission and human baroreflex regulation. Hypertension. 2004;43:1035-1041.
40. Sargent PB. The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci. 1993;16:403-443.
41. Buccafusco JJ. The role of central cholinergic neurons in the regulation of blood pressure and in experimental hypertension. Pharmacol Rev. 1996;48:179-211.
42. O'Connor DT, Frigon RP. Chromogranin A, the major catecholamine storage vesicle soluble protein: multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem. 1984;259:3237-3247.
43. Somogyi P, Hodgson AJ, DePotter RW, Fischer-Colbrie R, Schober M, Winkler H, Chubb IW. Chromogranin immunoreactivity in the central nervous system: immunochemical characterisation, distribution and relationship to catecholamine and enkephalin pathways. Brain Res. 1984;320:193-230.
44. Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the human angiotensin converting enzyme. Nat Genet. 1999;22:59-62.